Authors
Emma Vang Frandsen, Christian Lodberg Hvas, Simon Mark Dahl Baunwall, Rasmus Blechingberg Friis, Louise Mahncke Guldbrandt, Henrik Schmidt
Published in
Best practice & research. Clinical gastroenterology. Volume 83. Pages 102152. Epub Oct 07, 2026.
Abstract
Immune checkpoint inhibitors (ICIs) are pivotal in cancer treatment, but some patients develop resistance. In this systematic review, we aimed to summarise efficacy and safety of faecal microbiota transplantation (FMT) to enhance ICI therapy responses in patients with solid cancers.
We systematically searched PubMed, Embase and Web of Science on May 12, 2025 for studies evaluating FMT in combination with ICI for solid cancers.
We included five clinical trials, of which none included comparator therapy, describing 78 patients. Notably, some patients previously refractory to anti-PD-1 therapy achieved partial or complete responses following FMT combined with ICIs. Assessing safety, 76% had grade 1-2 adverse events, and grade ≥3 events were only observed after ICI initiation.
Small uncontrolled studies indicate a potential effect for FMT to enhance efficacy of ICI therapy without increasing toxicity.
PMID:
42971666
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0